<DOC>
	<DOCNO>NCT03045913</DOCNO>
	<brief_summary>This registry clinical post-market evaluation Genoss DES subject require coronary revascularization Drug Eluting Stents ( DES ) .</brief_summary>
	<brief_title>Genoss DES Prospective Multicenter Registry</brief_title>
	<detailed_description>Percutaneous coronary intervention ( PCI ) main stream treatment coronary artery disease . Drug-eluting stent ( DES ) dramatically reduce rate restenosis target lesion revascularization ( TLR ) compare bare-metal stent ( BMS ) . Newer-generation DES durable polymer Xience ( Abbott , US ) Resolute ( Medtronic , US ) widely use . However , concern late stent thrombosis due hypersensitivity reaction polymer still exist . Recently , DES biodegradable polymer Biomatrix ( Biosensors , Switzerland ) , Nobori ( Terumo , Japan ) , Orsiro ( Biotronik , Switzerland ) , Synergy ( Boston Scientific , US ) rapidly adopt expect reduce late stent thrombosis . Recently , new biodegradable DES thin strut develop South Korea . The Genoss DES ( Genoss , Korea ) L-605 cobalt chromium ( CoCr ) platform strut thickness 70 µm stent coat combination Sirolimus drug concentration 1.15µg/mm2 abluminal biodegradable PLA PLGA polymer . This study conduct evaluate efficacy safety Genoss DES treatment patient coronary artery disease .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Subject ≥ 19 year Subject implant Genoss DES within 1 month Subject sign informed consent data release Subject geographically stable willing participate followup assessment Subject sign inform consent data release Known intolerance aspirin , clopidogrel , ticlopidine , heparin anticoagulation / antiplatelet therapy require PCI , cobalt chromium , Sirolimus contrast medium Pregnancy Subject life expectancy le 12 month Subject cardiogenic shock Planned surgery within 12 month PCI unless dual antiplatelet therapy maintain Currently participate another study primary endpoint reach yet .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Observational registry</keyword>
	<keyword>All-comers open label registry</keyword>
	<keyword>Genoss DES</keyword>
	<keyword>Multicenter</keyword>
	<keyword>Stenting</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary revascularization</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
</DOC>